Clinical Trial

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-10-21; most recent amendment 2026-04-28.
Trial Details
NCT Number NCT04604509
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Cigarette Smoking-Related Carcinoma
Enrollment 2,010 participants
Start Date 2020-08-04
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04